Cytokinetics, Incorporated
CYTK
Rankning i aktier
#2260
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aktiekurs
$64.58
Marknadsvärde
$8.98B
Förändring (1 dag)
0.99%
Förändring (1 år)
11.77%
Land
US
Handel Cytokinetics, Incorporated (CYTK)
Kategori
Healthcare
Intäkter för Cytokinetics, Incorporated (CYTK)
Intäkter i Jun 2026 TTM: $70.96M
Enligt Cytokinetics, Incorporated senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $70.96M. År 2023 hade företaget intäkter på $7.53M en minskning jämfört med intäkterna år 2022, som var $94.59M. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäktshistorik för Cytokinetics, Incorporated från 2000 till 2026
Intäkter vid slutet av varje år
| År | Intäkter | Ändra |
|---|---|---|
| 2026 (TTM) | $70.96M | 284.11% |
| 2024 | $18.47M | 145.34% |
| 2023 | $7.53M | -92.04% |
| 2022 | $94.59M | 34.30% |
| 2021 | $70.43M | 26.15% |
| 2020 | $55.83M | 107.79% |
| 2019 | $26.87M | -14.71% |
| 2018 | $31.50M | 135.64% |
| 2017 | $13.37M | -87.44% |
| 2016 | $106.41M | 271.30% |
| 2015 | $28.66M | -38.95% |
| 2014 | $46.94M | 53.16% |
| 2013 | $30.65M | 305.45% |
| 2012 | $7.56M | 88.98% |
| 2011 | $4.00M | 55.22% |
| 2010 | $2.58M | -96.84% |
| 2009 | $81.54M | 556.51% |
| 2008 | $12.42M | -8.82% |
| 2007 | $13.62M | 335.63% |
| 2006 | $3.13M | -64.91% |
| 2005 | $8.91M | -33.70% |
| 2004 | $13.44M | 27.09% |
| 2003 | $10.58M | -7.19% |
| 2002 | $11.40M | 34.61% |
| 2001 | $8.47M | 0.00% |
| 2000 | 0.00 | 0.00% |
Intäkter för liknande företag eller konkurrenter
| Företag | Intäkter | Intäktsdifferens | Land |
|---|---|---|---|
| $12.62B | 17,690.73% |
US
|
|
| $2.23B | 3,039.80% |
US
|
|
| $15.74B | 22,087.61% |
AU
|
|
| $6.02B | 8,385.47% |
NL
|
|
| - | - |
CH
|
